Tesamorelin против Sermorelin
Что выбрать? Полное сравнение (2026)
Tesamorelin против Sermorelin — одобренный FDA аналог GHRH для снижения висцерального жира против классического пептида GHRH.
Tesamorelin против Sermorelin: Краткий обзор
Tesamorelin
- ✓Одобрен FDA (Egrifta) для ВИЧ-ассоциированной липодистрофии
- ✓Эффективен для уменьшения глубокого висцерального жира
- ✓Более длительный период полураспада по сравнению с серморелином
- ✓Стимулирует естественную пульсацию ГР
Sermorelin
- ✓Классический пептид GHRH(1-29)
- ✓Широко используется в антивозрастной терапии
- ✓Короткий период полураспада (10-20 мин)
- ✓Обычно вводится перед сном для имитации ночного пика ГР
Detailed Comparison
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| Mechanism | GHRH analogue | Growth hormone releasing hormone analogue |
| Dosing | 2 mg SC daily | 200-500 mcg SC daily at bedtime |
| Administration | Subcutaneous injection daily | Subcutaneous injection |
| Half-life | ~26-38 minutes | ~10-20 minutes |
| FDA Status | FDA-approved (Egrifta — for HIV lipodystrophy) | Previously FDA-approved (discontinued commercially) |
| Key Trial | Falutz J et al. NEJM 2007 — visceral fat reduction in HIV | Prakash A et al. BioDrugs 1999 — clinical review |
| Side Effects | Injection site reactions, joint pain, peripheral edema, paresthesia | Injection site reactions, flushing, headache — generally well-tolerated |
Which Should You Choose?
Tesamorelin (Egrifta) (ghrh analogue) and Sermorelin (GRF 1-29) (growth hormone releasing hormone analogue) serve different clinical roles despite both being in the GHRH analogue space. Tesamorelin (Egrifta) fda-approved synthetic ghrh analogue that stimulates pulsatile gh release. Sermorelin (GRF 1-29) synthetic 29-amino-acid analogue of natural ghrh that stimulates physiological gh release from the pituitary.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Track Both in Shotlee
Shotlee supports tracking any medication or peptide. Compare your results across different protocols with clean dose logs and outcome data.
Making an Informed Choice Between Tesamorelin and Sermorelin
Choosing between Tesamorelin and Sermorelin depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Tesamorelin and Sermorelin is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Tesamorelin vs Sermorelin: Часто задаваемые вопросы
Тезаморелин более специфичен для борьбы с висцеральным жиром и имеет большую стабильность. Серморелин — более доступный и изученный вариант для общей поддержки уровней гормона роста.
Источники
- [1]Clinical TrialFalutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." N Engl J Med. 2007;357(23):2359-2370.
- [2]Clinical TrialStanley TL, et al. "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation." JAMA. 2014;312(4):380-389.
- [3]Clinical TrialKhorram O, et al. "Two years of treatment with recombinant human growth hormone-releasing hormone (sermorelin) in healthy elderly men." J Clin Endocrinol Metab. 1997;82(11):3590-3596.
- [4]FDAU.S. Food and Drug Administration. "FDA Approves Egrifta (tesamorelin) to Treat Excess Abdominal Fat in HIV Patients." FDA News Release. November 10, 2010.
Отслеживайте Tesamorelin или Sermorelin в Shotlee
Бесплатный трекинг дозировок, учет побочных эффектов и сравнение результатов для любого протокола лечения.
🚀 Использовать Shotlee бесплатно